| Autor: |
Michael Böhm, Birgit Assmus, Stefan D. Anker, Folkert W. Asselbergs, Johannes Brachmann, Marie‐Elena Brett, Jasper J. Brugts, Georg Ertl, AiJia Wang, Lutz Hilker, Friedrich Koehler, Stephan Rosenkranz, David M. Leistner, Amr Abdin, Jan Wintrich, Qian Zhou, Philip B. Adamson, Christiane E. Angermann |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
ESC Heart Failure, Vol 9, Iss 1, Pp 155-163 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2055-5822 |
| DOI: |
10.1002/ehf2.13665 |
| Popis: |
Abstract Aims Control of pulmonary pressures monitored remotely reduced heart failure hospitalizations mainly by lowering filling pressures through the use of loop diuretics. Sacubitril/valsartan improves heart failure outcomes and increases the kidney sensitivity for diuretics. We explored whether sacubitril/valsartan is associated with less utilization of loop diuretics in patients guided with haemodynamic monitoring in the CardioMEMS European Monitoring Study for Heart Failure (MEMS‐HF). Methods and results The MEMS‐HF population (n = 239) was separated by the use of sacubitril/valsartan (n = 68) or no use of it (n = 164). Utilization of diuretics and their doses was prespecified in the protocol and was monitored in both groups. Multivariable regression, ANCOVA, and a generalized linear model were used to fit baseline covariates with furosemide equivalents and changes for 12 months. MEMS‐HF participants (n = 239) were grouped in sacubitril/valsartan users [n = 68, 64 ± 11 years, left ventricular ejection fraction (LVEF) 25 ± 9%, cardiac index (CI) 1.89 ± 0.4 L/min/m2] vs. non‐users (n = 164, 70 ± 10 years, LVEF 36 ± 16%, CI 2.11 ± 0.58 L/min/m2, P = 0.0002, P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text